A new antiviral candidate targets a virus family with major gaps in treatment
Researchers at Georgia State University say they have identified a once-daily oral antiviral candidate that could open a new front against a group of dangerous respiratory viruses that still lack reliable treatment options. In a study published in Science Advances, the team describes GHP-88310 as a clinical candidate designed for diseases caused by orthoparamyxoviruses, a family that includes measles virus, human parainfluenzaviruses and emerging henipaviruses.
The work arrives at a moment when several of those pathogens are drawing renewed concern. Human parainfluenzavirus type 3 remains a serious threat for older adults, immunocompromised patients and stem cell transplant recipients, while measles has resurged in recent months across large parts of the United States, Mexico and Canada. The researchers argue that the lack of approved vaccines or therapeutics for some of these infections leaves a significant unmet medical need, especially for vulnerable groups.
Why the target matters
Orthoparamyxoviruses are not a single-disease problem. They include viruses that can trigger severe pneumonia, croup syndrome and other respiratory illness, and they can be especially dangerous for children and patients whose immune systems are weakened. That breadth is part of what makes the Georgia State result notable: the drug discovery effort was built around a virus family rather than a single outbreak.
Lead author Carolin Lieber said the team initially focused on human parainfluenzavirus type 3 as the main clinical indication for development. Senior author Richard Plemper said the program was deliberately structured to address patient populations with the fewest options. The researchers describe GHP-88310 as the most promising inhibitor they have seen in years of work on this virus class.
How the candidate was found
According to the study summary, the research team began with a large high-throughput screening campaign to identify compounds with antiviral potential. From there, they optimized an early lead into what they now consider a clinical candidate. The article does not frame the result as a finished medicine; instead, it presents GHP-88310 as the product of a longer translational pipeline aimed at moving from lab hit to development-ready antiviral.
That distinction matters. Many antiviral projects stall after showing basic activity in cell systems. Here, the researchers report efficacy in both rodent and non-rodent animal models of infection, a step that gives the candidate more weight than a narrow proof-of-concept finding. Even so, animal-model success does not guarantee that a drug will work safely or effectively in people.
A dual public-health relevance
The candidate’s potential role against parainfluenzaviruses may be the most immediately underappreciated part of the study. These infections do not always dominate headlines, but they place a substantial burden on health systems. The researchers cite an estimated 3 million U.S. cases each year requiring treatment for parainfluenzavirus-related disease. For high-risk adults, that can include life-threatening pneumonia.
Measles, by contrast, is a more visible concern because outbreaks have returned in areas where public-health authorities had hoped control was stronger. The Georgia State team positions GHP-88310 as a possible secondary indication for measles, suggesting the platform could matter both for routine severe respiratory disease and for resurgent vaccine-preventable infections that still need therapeutic backup when prevention fails.
What makes this result important
The most significant aspect of the report is not simply that another antiviral has been proposed. It is that the researchers say they have identified a candidate aimed at a virus family for which treatment choices remain thin or nonexistent. That gives the work strategic value: one well-designed molecule could potentially serve multiple clinically important infections rather than a single narrow use case.
The study also reflects a broader shift in antiviral research toward preparedness. Instead of waiting for an outbreak to force rapid, reactive drug development, laboratories are increasingly trying to build reusable therapeutic platforms in advance. A candidate that can be adapted across related viruses fits that approach, particularly when the targeted pathogens include both established childhood infections and emerging zoonotic threats.
The next hurdle is translation
The findings remain preclinical, and the usual cautions apply. Animal-model efficacy is an important step, not a guarantee of clinical success. Developers will still need to establish safety, dosing, pharmacology and real-world antiviral effect in human trials. The article also does not suggest that a regulatory filing is imminent.
Still, the signal is strong enough to mark this as more than an incremental lab update. If GHP-88310 continues to perform well, it could become a rare example of a broadly useful oral antiviral developed for a medically neglected virus family. In an era shaped by both re-emerging infections and pressure for faster-response therapeutics, that would be a meaningful advance.
This article is based on reporting by Medical Xpress. Read the original article.
Originally published on medicalxpress.com
